Advisory Board October 21, 2025

FDA last week approved the first blood test to help assess Alzheimer’s disease and other causes of cognitive decline in primary care settings, in today’s bite-sized hospital and health industry news from Maryland, Pennsylvania, and Washington.

  • Maryland: FDA has approved the first blood-based biomarker test to help providers assess patients for Alzheimer’s disease and other causes of cognitive decline in primary care settings. The test, which is called Elecsys pTau181, measures plasma levels of phosphorylated tau 181 (p-tau181). P-tau 181 is a key marker of amyloid plaque and tau aggregate pathology associated with Alzheimer’s disease. The test is intended for patients ages 55 and older who have symptoms or complaints of cognitive decline and should be used alongside...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies, Primary care, Provider
Related Articles:
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 1)

Share Article